Revenue: The sum of all revenue fields included for a company's operating activities.
Inhibikase Therapeutics, Inc. (IKT) Revenue data is not available for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
|
Revenue |
-- |
$-13.68M |
|
-- |
|
-- |
|
$14.60M |
|
$-14.60M |
|
$0.92M |
|
$-13.68M |
|
$-13.68M |
|
$-13.68M |
|
$-13.68M |
|
$-13.68M |
|
$-13.68M |
|
$-14.60M |
|
$-14.59M |
|
89.54M |
|
89.54M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$94.16M |
|
$0.05M |
|
$0.12M |
|
$94.28M |
|
$8.55M |
|
-- |
|
-- |
|
$8.55M |
|
$85.73M |
|
$85.73M |
|
$85.73M |
|
74.34M |
|
| Cash Flow Statement Financials | |
$-4.10M |
|
$21.05M |
|
-- |
|
$56.49M |
|
$73.44M |
|
$16.95M |
|
$2.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.96% |
|
-15.96% |
|
-14.51% |
|
-15.96% |
|
$1.15 |
|
$-0.05 |
|
$-0.05 |
|